What Comes Second?

Progressive Nature of T2D

Review of Second-Line Therapy

Consider Drug-Specific Effects

AACE/ACE Recommendations

SUs and DPP-4 Inhibitors

Consider Key Characteristics of Antidiabetic Medications

Glycemic Durability

New Data Examining Long-Term Efficacy for Second-Line T2D

Greater Durability With DPP-4 Inhibitors vs SUs

Less Hypoglycemia Risk With DPP-4 Inhibitors

Clinical Inertia

HbA1c and Beta-Cell Preservation

Rationale for Better Long-Term Control

Closing Comments

Abbreviations

Abbreviations (cont)